AVI BioPharma Inc., of Portland, Ore., appointed Christopher S. Henney and M. Kathleen Behrens to its board...Richmond, Calif., appointed Joseph T. Kennedy vice president, general counsel and secretary...Dafna Cohen and Yaron Diament were appointed external directors

Hanall Pharmaceuticals, of Seoul, South Korea, appointed Andrew J. Gorman vice president and chief of corporate development...Micromet Inc., of Bethesda, Md., named Walter Bodmer and Bernard Fox to its BiTE antibody advisory panel...Myers, Fla., named Douglas M. VanOort to the board as executive chairman and interim CEO

Bioheart Inc., of Sunrise, Fla., named Michael Brown and Judy Brown research consultants...PDL BioPharma Inc., of Incline Village, Nev., elected Frederick Frank and Jody Lindell to its board...Savara Inc., of Austin, Texas, elected Nevan Elam, Curt Bilby and Matthew Dennis to its board

AVI BioPharma Inc., of Portland, Ore., appointed Stephen B. Shrewsbury chief medical officer and senior vice president of clinical and regulatory affairs Biota Holdings Ltd., of Melbourne, Australia, appointed James Fox as a nonexecutive director and chairman...WuXi PharmaTech, of Shanghai, China, added Stewart Hen and Ning Zhao to its board...XTL Biopharmaceuticals Ltd., of Valley Cottage, N.Y., appointed David Grossman and Boaz Shweiger to its board

Aerovance Inc., of Berkeley, Calif., appointed Babatunde A. Otulana senior vice president and chief medical officer...F2G Ltd., of Manchester, UK, appointed Tony Kennedy chief scientific and development officer...Gentel Biosciences, of Madison, Wis., promoted G. Randall Durnell to executive vice president and chief operating officer

Pluristem Therapeutics Inc., of New York, appointed Frida Grynspan vice president of research and development...PDL BioPharma Inc., of Incline Village, Nev., appointed Christopher L. Stone vice president, general counsel and secretary

and Krish Venkat senior vice president of quality Cell Targeting Inc., of Cleveland, appointed Joseph Wagner chief technology officer...and Paul H. Granger vice president and general counsel

Sinobiomed Inc., of Shanghai, China, named Anchie Kuo president and CEO...Brent Suen head of strategic development and mergers and acquisitions

MorphoSys AG, of Martinsried, Germany, appointed Ulrich Moebius head of preclinical development and project management...He also will provide strategic direction to Novacta's R&D team and will become chairman of the scientific advisory board...Pharminox Ltd., of Nottingham, UK, appointed Lee Arnold, Adrian Harris and Robert Jackson to its scientific advisory board

New Leaf Venture Partners, of New York, named Srinivas Akkaraju managing director and to lead its West Coast biopharmaceuticals practice...OncoMethylome Sciences, of Liege, Belgium, named Gerard Vaillant to its board, and appointed Gert-Jan Renardel de Lavalette chief operating officer

Sander van Deventer, AMT's chief scientific officer and co-founder of the company, has been named interim CEO...Ligand Pharmaceuticals Inc., of San Diego, named Bruce A. Peacock and Steven J. Burakoff to its board...The company also added former FDA official Marianne Mann and former Merck & Co

The company also added former FDA official Marianne Mann and former Merck & Co...XOMA Ltd., of Berkeley, Calif., appointed Fred Kurland vice president of finance and chief financial officer

Clarus Ventures LLC, of Cambridge, Mass., promoted Emmett Cunningham to partner and Scott Requadt to transactional partner...Ensysce Biosciences Inc., of Houston, appointed Lynn Kirkpatrick president and CEO...ONI BioPharma Inc., of Alachua, Fla., named Martin Handfield director of research and development

and Steve Neben senior director of project and alliance management...Oxigene Inc., of Waltham, Mass., named Nicole Onetto and Eric K. Rowinsky to the board of its subsidiary Symphony ViDA Inc

TyRx Inc., of Monmouth Junction, N.J., appointed William G. Dempsey an independent director. Vitae Pharmaceuticals Inc., of Fort Washington, Pa., promoted Tina Fiumenero to chief financial officer. XOMA Ltd., of Berkeley, Calif., appointed Stephen K. Doberstein vice president of research.

Prognostix Inc., of Cleveland, appointed Jake Orville president and CEO...Thomas Hecht was appointed chairman, and Michael Motschmann will join the board...SuppreMol also named Fritz Melchers and Falk Nimmerjahn to its scientific advisory board

NuPathe Inc., of Conshohocken, Pa., appointed Keith A. Goldan vice president and chief financial officer...PDL BioPharma Inc., of Redwood City, Calif., elected Paul W. Sandman and John P. McLaughlin to its board...Potential Pharmaceuticals, of Louisville, Ky., appointed Johanna M. Seddon and Janet Stoltz Sunness to its scientific advisory board

ImmunoGen Inc., of Waltham, Mass., appointed James J. O'Leary vice president and chief medical officer...Infinity Pharmaceuticals Inc., of Cambridge, Mass., promoted Adelene Q. Perkins president and chief business officer...It also appointed Bruce R. Thaw chairman and named James E. Rothman chairman of the scientific advisory board

The company appointed Craig A. Collard president and CEO and named Alastair McEwan chairman...It also appointed Christopher Codeanne, Michael Enright and Michael Heffernan to the board